Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.
Gilbert
Matthew P
MP
Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA.
Pratley
Richard E
RE
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*; D016896:Treatment Outcome
D054795:Incretins